Meeting
2014 ASCO Annual Meeting
HIP1 expression and response to chemotherapy in breast cancer.
Authors
Mireia Margeli
Institut Català d'Oncologia - Hospital Germans Trias i Pujol, Badalona, Spain
Mireia Margeli , Vanesa Quiroga , Eva Castella , Gustavo Tapia , Montserrat Sola , Maria Sanchez-Ronco , Joaquim Radua , Cristina Buges , Laia Espasa , Laia Capdevila , Miguel Angel Luna , Rosa Ballester , Javier Arce , Antonio Mariscal , Sara Vizcaya , Laia Vila , Alberto Indacochea , Agusti Barnadas , Rafael Rosell , Beatriz Cirauqui
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1046)
DOI
10.1200/jco.2014.32.15_suppl.1046
Abstract #
1046
Poster Bd #
139
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer.
First Author: Naoko Matsuda
Poster
2017 ASCO Annual Meeting
Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.
First Author: Julia Foldi
Poster
2014 ASCO Annual Meeting
Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.
First Author: Kenji Tamura
Poster
2014 ASCO Annual Meeting
Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy.
First Author: Joyce O'Shaughnessy